GLP-1 and GIP co-agonist compounds
By developing dual agonist compounds based on human GIP polypeptides, the problems of poor plasma stability and side effects of GLP-1 analogs and GIP analogs were solved, and stronger blood sugar control and weight loss effects were achieved, supporting once-week subcutaneous injections to drugs enhance the therapeutic effect on non-insulin-dependent diabetes and obesity.
Patent Information
- Application Number
- CN202010305152.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-04-19
- Filing Date
- 2020-04-17
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-04-17
AI Technical Summary
The existing GLP-1 analogs and GIP analogs have poor plasma stability, high renal clearance rate and side effects such as nausea, vomiting, diarrhea, etc., which are difficult to effectively control blood sugar and weight, and the risk of pancreatitis increases. Limits its dosage and efficacy.
A dual agonist compound based on human GIP polypeptides has been developed that has a dual agonist effect on human GLP-1 receptors and GIP receptors, and improves plasma stability through specific amino acid modifications and fatty acid modifications, supporting once a week subcutaneous subcutaneously Injection and administration enhance the efficacy of reducing blood sugar and weight loss.
It achieves higher plasma stability and stronger efficacy in reducing blood sugar and weight loss, reduces side effects, supports weekly subcutaneous injections, and improves the efficacy of treating non-insulin-dependent diabetes and obesity.
Smart Images

Figure BDA0002455485270000131 
Figure BDA0002455485270000151 
Figure BDA0002455485270000161
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a compound that has a dual agonist effect on human glucagon-like peptide-1 (GLP-1) receptor and human glucose-dependent insulinotropic polypeptide (GIP) receptor, and can be used to treat metabolic diseases such as non-insulin-dependent diabetes, insulin-dependent diabetes, obesity and other related diseases. Background Art
[0002] Diabetes is a metabolic disease caused by insufficient insulin secretion in the body, which leads to dysregulation of glucose, protein and lipid metabolism in the human body. According to the differences in their pathological mechanisms, diabetes is mainly divided into insulin-dependent diabetes (type I diabetes) and non-insulin-dependent diabetes (type II diabetes). Among them, 90-95% of diabetic patients worldwide are non-insulin-dependent diabetes. Non-insulin-dependent diabetes is a long-term, chronic metabolic disease caused by impaired pancreatic β-cell function and long-term insulin resistance. Its most important characteristics are the lack of insulin levels in the body and high blood sugar concentrations in plasma. Studies have shown that non-insulin-dependent diabetes is associated with a variety of high-risk complications in patients, and it often causes patients to suffer from cardiovascular disease, kidney failure, blindness, amputation and many other complications.
[0003] One of the main causes of non-insulin-dependent diabetes is obesity. Obesity is defined as excessive or abnormal fat accumulation in the body that is harmful to human health. According to a person's body mass index (BMI), obesity can also be defined as a person's BMI index greater than or equal to 30kg / m 2 The emergence of obesity significantly increases the risk of cardiovascular disease, diabetes, musculoskeletal diseases and certain cancers. In addition, an increase in body mass index also increases the risk of certain non-communicable diseases.
[0004] Because of the huge number of patients with diabetes and its complications and the significant economic burden on people, the development of safe and effective drugs for the treatment of diabetes has always been the focus of many research institutions and pharmaceutical companies. At present, the diabetes drugs that have been approved for marketing mainly include chemically synthesized small molecule oral hypoglycemic drugs, such as biguanides, sulfonyls, insulin sensitizers, α-glycosides, and injectable hypoglycemic drugs such as recombinant insulin and its derivatives produced by biosynthesis. Although the above drugs can effectively control the blood sugar level in the plasma of diabetic patients clinically, their long-term use is often accompanied by adverse reactions such as weight gain in patients, which in turn leads to an increase in the risk of potential cardiovascular diseases and a decrease in patient compliance. Considering the potential pathological relationship between diabetes and obesity and the potential risk of complications caused by obesity, the development of a drug that can effectively control blood sugar and appropriately reduce the weight of diabetic patients has multiple meanings for the effective treatment of diabetes and the reduction of potential complications. Therefore, the development of new drugs for the treatment of diabetes is urgently needed clinically.
[0005] Glucagon like peptide-1 (GLP-1) is a gastrointestinal regulatory polypeptide containing 30 or 31 amino acid residues. The secretion of GLP-1 is mainly regulated by the L-cells in the small intestine according to the absorption of nutrients and the fluctuating blood sugar level in the body. After food intake, the L-cells in the small intestine secrete a large amount of GLP-1 to enhance the endocrine function of the pancreas. The GLP-1 polypeptide mainly completes its physiological function of controlling blood sugar and reducing appetite in the body by activating the GLP-1 receptors distributed on the surface of the cell membrane. The mechanism by which GLP-1 controls blood sugar levels in the body is mainly to activate its GLP-1 receptors distributed in the pancreatic β cells to promote the biosynthesis and secretion of insulin. At the same time, the GLP-1 polypeptide can inhibit the secretion of glucagon, gastric emptying and food intake under the condition of high blood sugar levels in the body and enhance the degradation of glucose in the body through specific nervous system effects. It is worth noting that the physiological function of the GLP-1 polypeptide to promote insulin secretion is highly controlled by the plasma glucose concentration. Therefore, compared with other diabetes treatment drugs, the GLP-1 polypeptide will not cause severe and persistent hypoglycemia. In addition, the literature reports that GLP-1 polypeptide and its analogs have a direct promoting effect on the growth, differentiation and proliferation of β cells in experimental animals, indicating that GLP-1 polypeptide and its analogs can protect the physiological functions of pancreatic islets and delay the progression of diabetes and inhibit the apoptosis of β cells. GLP-1 polypeptide also has the potential to inhibit gastrin and gastric acid secretion stimulated by food intake. These characteristics mean that GLP-1 polypeptide also has the physiological effect of preventing gastrointestinal ulcers. GLP-1 polypeptide can also activate its GLP-1 receptor distributed in the central nervous system of the brain to enhance satiety, reduce food intake and achieve the physiological effect of maintaining or reducing body weight. Therefore, the wide range of mechanisms of action and physiological functions of GLP-1 polypeptide and its analogs mean that GLP-1 polypeptide is an ideal drug for the treatment of non-insulin-dependent diabetes and obese diabetes.
[0006] The physiological functions of GLP-1 peptides in controlling blood sugar and reducing body weight have brought hope for the treatment of non-insulin-dependent diabetes / obese diabetes. However, the drugability of natural GLP-1 in the human body is poor. It is easily degraded by dipeptidyl peptidase-IV (DPP-IV) in the body, so that its half-life in the human body is only 1-2 minutes. Faced with this difficulty, the pharmaceutical industry has constructed long-acting GLP-1 analogs and their derivatives by performing site-directed mutation of amino acids at enzyme cleavage sites, fatty acid modification of polypeptide skeletons, and binding of GLP-1 peptides to various proteins / polymers. At present, long-acting GLP-1 analogs that have been marketed and widely used in clinical practice include enasetide, which is administered by subcutaneous injection twice a day, liraglutide, which is administered by subcutaneous injection once a day, and dulaglutide and semaglutide, which are administered by subcutaneous injection once a week.
[0007] Clinically, the side effects of GLP-1 polypeptide and its derivatives are mainly nausea, vomiting and diarrhea caused by the gastrointestinal tract; in addition, it has been found that GLP-1 polypeptide and its derivatives can also cause the subjects' heart rate to accelerate and increase the risk of pancreatitis in certain cases. Therefore, the dosage of GLP-1 polypeptide and its derivatives is limited by the side effects they cause, so their clinical use cannot effectively achieve blood sugar control and weight loss in patients.
[0008] Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 peptide are both incretins, which play a key physiological role in the metabolism of blood glucose in the body. GIP is mainly composed of 42 amino acid residues in the body and is secreted by duodenum and adjacent jejunum K cells according to the glucose level in plasma. GIP peptide exerts its physiological effects by binding to its GIP receptors distributed in pancreatic β cells, adipose tissue and central nervous system. Similar to GLP-1 peptide, GIP peptide can stimulate pancreatic β cells to secrete insulin to reduce the blood glucose concentration in plasma and protect pancreatic β cells to control the metabolism of glucose in the body. In addition, the physiological function of GIP peptide also includes activating its GIP receptor in adipose tissue to promote fat metabolism. Interestingly, intracerebroventricular injection of GIP peptide in mice can reduce the food intake and body weight of the test animals, which seems to indicate that GIP peptide also has certain specific physiological functions in reducing body weight. Studies have shown that the incretin function of GIP polypeptides in non-insulin-dependent diabetic patients is greatly reduced, resulting in the lack or loss of incretin effects in patients. Studies have shown that the inhibitory effect of GIP polypeptides produced by these diabetic patients will be greatly weakened when blood sugar levels return to normal. Therefore, a clinical method of using GIP polypeptides to treat non-insulin-dependent diabetes is to restore the tolerance of non-insulin-dependent diabetic patients to GIP polypeptides in combination with some clinically effective hypoglycemic drugs and further utilize the incretin effect of GIP polypeptides to obtain stronger hypoglycemic effects.
[0009] Some GLP-1 / GIP receptor dual agonist compounds based on the natural GIP polypeptide sequence have been described in WO2011 / 119657, WO2013 / 164483 and WO2014 / 192284.
[0010] A major drawback of polypeptide compounds as drugs is their extremely poor stability in plasma in vivo. This is mainly due to the hydrolysis of amide bonds between amino acids in the polypeptide sequence by enzymatic reactions and the renal clearance caused by the small molecular weight of the polypeptide compound. It has been found that the introduction of non-natural amino acids or lipophilic substituents, such as fatty acid modification, at specific sites in the polypeptide sequence can improve the enzymatic hydrolysis stability of a given peptide and inhibit the renal clearance of the polypeptide compound. Among them, fatty acids improve the pharmacokinetic properties of polypeptide drugs by combining with albumin in plasma, thereby reducing the renal clearance rate. At the same time, the present invention also notes that the length, structure and binding site of fatty acids with polypeptides have a certain effect on the biological activity of polypeptide compounds.
[0011] Therefore, compared with many GIP receptor selective agonist polypeptides in the art, the purpose of the present invention is to provide a GIP analog and its derivatives having agonist activity on human GLP-1 receptor, which have dual agonist effects on human GLP-1 receptor and human GIP receptor. In addition, certain compounds of the present invention have stronger efficacy in lowering blood sugar and reducing body weight than GLP-1 receptor agonists in the art. Finally, certain compounds of the present invention have extremely high plasma stability and have pharmacokinetic characteristics that support once-weekly subcutaneous injection administration in humans. Summary of the invention
[0012] The purpose of the present invention is to provide some dual agonist compounds based on human GIP polypeptide, which have dual agonist effects on human GLP-1 receptor and GIP receptor. In addition, some polypeptide compounds and derivatives provided by the present invention have higher plasma stability than human natural GLP-1 polypeptide and human natural GIP polypeptide, and can support the pharmacokinetic characteristics of once-weekly subcutaneous injection in humans. Another purpose of the present invention is to provide a pharmaceutical composition containing derivatives of the above-mentioned polypeptide dual agonist compounds and pharmaceutically acceptable salts thereof, which can be used to treat metabolic diseases such as non-insulin-dependent diabetes, insulin-dependent diabetes and obesity.
[0013] Therefore, one embodiment of the present invention is to provide a polypeptide compound based on the human GIP sequence and its derivatives or pharmaceutically acceptable salts thereof as shown in the following formula:
[0014] R1-Tyr-X1-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X2-Ser-Ile-X3-Nle-X4-Y1-X5-X6-X7-X8-X9-Phe-X10-X11-Trp-Leu-X12-X13-X14-X15-X16-R2
[0015] (I)
[0016] in:
[0017] X1-X16 or Y1 is independently selected from any natural amino acid or non-natural amino acid or a peptide consisting of the same or does not exist;
[0018] R1 is selected from H, alkyl, acetyl, formyl, benzoyl, trifluoroacetyl or pGlu;
[0019] R2 is selected from -NH 2 or -OH;
[0020] The preferred solution is:
[0021] R1 is H;
[0022] R2 is -NH 2 .
[0023] The preferred embodiment of the present invention is:
[0024] X1 is an amino acid residue selected from Ala, Aib or D-Ala;
[0025] X2 is an amino acid residue selected from Leu or Try;
[0026] X3 represents an amino acid residue selected from Ala, Gln or Tyr;
[0027] X4 is an amino acid residue selected from Glu or Asp;
[0028] X5 is an amino acid residue selected from Glu, Ile or Gln;
[0029] X6 is selected from the group consisting of His, Ala or Aib amino acid residues;
[0030] X7 is selected from a Gln or Val amino acid residue;
[0031] X8 is an amino acid residue selected from Arg, Gln, Lys or Y1;
[0032] X9 is selected from Leu, Glu or Asp amino acid residues;
[0033] X10 is an amino acid residue selected from Ile or Val;
[0034] X11 is an amino acid residue selected from Asn, Ala, Glu or Gln;
[0035] X12 is selected from a Leu or Val amino acid residue;
[0036] X13 is selected from Ala or Arg amino acid residues;
[0037] X14 is selected from a Gln or Gly amino acid residue;
[0038] X15 is an amino acid residue selected from Lys, Gly or Y1;
[0039] X16 represents an amino acid sequence selected from the group consisting of: -Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-, -Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1- or is absent;
[0040] Y1 is selected from the amino acid residue of Lys or a side chain thereof having the formula ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(y-Glu) b -CO-(CH 2 ) c -COOH substituent coupled to Lys, Orn, Dap, Dab or Cys amino acid residues;
[0041] Wherein: a is an integer between 1 and 3, b is an integer between 1 and 2, and C is an integer between 10 and 20.
[0042] A further preferred embodiment of the present invention is to provide a polypeptide compound based on the human GIP sequence and its derivatives or pharmaceutically acceptable salts thereof as shown in the following formula, and its structure is as follows:
[0043] H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X2-Ser-Ile-X3-Nle-X4-Lys-X5-X6-X7-X8-X9-Phe-X10-X11-Trp-Leu-X12-Ala-X14-X15-NH 2 ,
[0044] in:
[0045] X2-X12, X14 and X15 are as described in claim 3.
[0046] A further preferred embodiment of the present invention is to provide a polypeptide compound based on the human GIP sequence and its derivatives or pharmaceutically acceptable salts thereof as shown in the following formula:
[0047] H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-X3-Nle-Glu-Lys-X5-X6-Gln-X8-X9-Phe-X10-X11-Trp-Leu-Leu-Ala-Gln-Lys-NH2
[0048] in:
[0049] X3, X5, X6, X8-X11 are as defined in the general formula (I).
[0050] A further preferred embodiment of the present invention is to provide a polypeptide compound based on the human GIP sequence and its derivatives or pharmaceutically acceptable salts thereof as shown in the following formula:
[0051] H-Tyr-X1-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X2-Ser-Ile-X3-Nle-X4-Lys-X5-X6-X7-X8-X9-Phe-X10-X11-Trp-Leu-X12-X13-X14-X15-X16-NH 2
[0052] wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, and X16 are each independently selected from any natural amino acid or non-natural amino acid or a peptide consisting thereof;
[0053] The derivatives of the polypeptide compounds are obtained by chemically modifying the polypeptide compounds using lipophilic substituents. Typical modification methods are amide bonds, ester bonds or thioether bonds, and the preferred modification method is amide bonds.
[0054] A preferred embodiment of the present invention is that in the polypeptide compound, X1 is selected from Ala, Aib, D-Ala; X2 is selected from Leu, Tyr; X3 is selected from Ala, Gln, Tyr; X4 is selected from Asp, Glu; X5 is selected from Ile, Gln, Glu; X6 is selected from Ala, Aib, His; X7 is selected from Gln, Val; X8 is selected from Gln, Lys, Arg, Y1; X9 is selected from Asp, Glu, Leu; X10 is selected from Ile, Val; X11 is selected from Ala, Asn, Glu, Gln; X12 is selected from Leu, Val; X13 is selected from Ala, Arg; X14 is selected from Gly, Gln; X15 is selected from Lys, Gly, Y1; X16 represents an amino acid sequence selected from Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1 or is absent;
[0055] Wherein Y1 represents a side chain having the formula ([2-(2-amino-ethoxy)-ethoxy]-acetyl) a -(y-Glu) b -CO-(CH 2 ) cA Lys, Orn, Dap, Dab or Cys amino acid residue coupled to a -COOH substituent; wherein: a is an integer between 1 and 3, b is an integer between 1 and 2, and C is an integer between 10 and 20.
[0056] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Ala, X7 is Gln, X8 is Lys, X9 is Glu, X10 is Ile, X11 is Ala, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent.
[0057] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Ala, X7 is Gln, X8 is Y1, X9 is Glu, X10 is Ile, X11 is Ala, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0058] In Y1, a is 2, b is 1, and c is 16 or 18.
[0059] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Ala, X7 is Gln, X8 is Lys, X9 is Glu, X10 is Ile, X11 is Ala, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Y1, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0060] In Y1, a is 2, b is 1, and c is 16 or 18.
[0061] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Ala, X7 is Gln, X8 is Lys, X9 is Glu, X10 is Ile, X11 is Ala, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1;
[0062] In Y1, a is 2, b is 1, and c is 16 or 18.
[0063] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Ala, X7 is Gln, X8 is Arg, X9 is Leu, X10 is Val, X11 is Glu, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent.
[0064] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Ala, X7 is Gln, X8 is Y1, X9 is Leu, X10 is Val, X11 is Glu, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0065] In Y1, a is 2, b is 1, and c is 16 or 18.
[0066] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Ala, X7 is Gln, X8 is Arg, X9 is Leu, X10 is Val, X11 is Glu, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Y1, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0067] In Y1, a is 2, b is 1, and c is 16 or 18.
[0068] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Ala, X7 is Gln, X8 is Arg, X9 is Leu, X10 is Val, X11 is Glu, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1;
[0069] In Y1, a is 2, b is 1, and c is 16 or 18.
[0070] In another preferred embodiment of the present invention, X1 is Aib, X2 is Leu, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Ala, X7 is Val, X8 is Arg, X9 is Leu, X10 is Ile, X11 is Asn, X12 is Leu, X13 is Ala, X14 is Gly, X15 is Gly, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent.
[0071] In another preferred embodiment of the present invention, X1 is Aib, X2 is Leu, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Ala, X7 is Val, X8 is Y1, X9 is Leu, X10 is Ile, X11 is Asn, X12 is Leu, X13 is Ala, X14 is Gly, X15 is Gly, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0072] In Y1, a is 2, b is 1, and c is 16 or 18.
[0073] In another preferred embodiment of the present invention, X1 is Aib, X2 is Leu, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Ala, X7 is Val, X8 is Arg, X9 is Leu, X10 is Ile, X11 is Asn, X12 is Leu, X13 is Ala, X14 is Gly, X15 is Y1, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0074] In Y1, a is 2, b is 1, and c is 16 or 18.
[0075] In another preferred embodiment of the present invention, X1 is Aib, X2 is Leu, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Ala, X7 is Val, X8 is Arg, X9 is Leu, X10 is Ile, X11 is Asn, X12 is Leu, X13 is Ala, X14 is Gly, X15 is Gly, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1;
[0076] In Y1, a is 2, b is 1, and c is 16 or 18.
[0077] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent.
[0078] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Ala, X7 is Gln, X8 is Y1, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0079] In Y1, a is 2, b is 1, and c is 16 or 18.
[0080] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Y1, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0081] In Y1, a is 2, b is 1, and c is 16 or 18.
[0082] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1;
[0083] In Y1, a is 2, b is 1, and c is 16 or 18.
[0084] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Aib, X7 is Gln, X8 is Lys, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent.
[0085] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Aib, X7 is Gln, X8 is Y1, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0086] In Y1, a is 2, b is 1, and c is 16 or 18.
[0087] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Aib, X7 is Gln, X8 is Lys, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Y1, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0088] In Y1, a is 2, b is 1, and c is 16 or 18.
[0089] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Gln, X6 is Aib, X7 is Gln, X8 is Lys, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1;
[0090] In Y1, a is 2, b is 1, and c is 16 or 18.
[0091] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent.
[0092] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Y1, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0093] In Y1, a is 2, b is 1, and c is 16 or 18.
[0094] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Y1, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0095] In Y1, a is 2, b is 1, and c is 16 or 18.
[0096] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Ile, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1;
[0097] In Y1, a is 2, b is 1, and c is 16 or 18.
[0098] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Val, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent.
[0099] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Y1, X9 is Glu, X10 is Val, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0100] In Y1, a is 2, b is 1, and c is 16 or 18.
[0101] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Val, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Y1, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0102] In Y1, a is 2, b is 1, and c is 16 or 18.
[0103] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Val, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1;
[0104] In Y1, a is 2, b is 1, and c is 16 or 18.
[0105] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Ile, X11 is Ala, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent.
[0106] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Y1, X9 is Glu, X10 is Ile, X11 is Ala, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is not present; in Y1, a is 2, b is 1, and c is 16 or 18. In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Ile, X11 is Ala, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Y1, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0107] In Y1, a is 2, b is 1, and c is 16 or 18.
[0108] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Tyr, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Ile, X11 is Ala, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1;
[0109] In Y1, a is 2, b is 1, and c is 16 or 18.
[0110] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Aib, X7 is Gln, X8 is Arg, X9 is Leu, X10 is Val, X11 is Glu, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent.
[0111] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Aib, X7 is Gln, X8 is Y1, X9 is Leu, X10 is Val, X11 is Glu, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0112] In Y1, a is 2, b is 1, and c is 16 or 18.
[0113] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Aib, X7 is Gln, X8 is Arg, X9 is Leu, X10 is Val, X11 is Glu, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Y1, X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0114] In Y1, a is 2, b is 1, and c is 16 or 18.
[0115] In another preferred embodiment of the present invention, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Glu, X6 is Aib, X7 is Gln, X8 is Arg, X9 is Leu, X10 is Val, X11 is Glu, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1;
[0116] In Y1, a is 2, b is 1, and c is 16 or 18.
[0117] In another preferred embodiment, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Val, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent.
[0118] In another preferred embodiment, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Y1, X9 is Glu, X10 is Val, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0119] In Y1, a is 2, b is 1, and c is 16 or 18.
[0120] In another preferred embodiment, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Val, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Y1, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser or is absent;
[0121] In Y1, a is 2, b is 1, and c is 16 or 18.
[0122] In another preferred embodiment, X1 is Aib, X2 is Tyr, X3 is Ala, X4 is Glu, X5 is Ile, X6 is Ala, X7 is Gln, X8 is Gln, X9 is Glu, X10 is Val, X11 is Gln, X12 is Leu, X13 is Ala, X14 is Gln, X15 is Lys, and X16 is Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Y1;
[0123] In Y1, a is 2, b is 1, and c is 16 or 18.
[0124] The present invention also relates to a preferred technical solution, having a GIP analogue or a pharmaceutically acceptable salt thereof as described in general formula (I), wherein Y1 is K(-OEG-OEG-yGlu-C18-OH), and the group has the following chemical formula:
[0125]
[0126] A further preferred technical solution of the present invention is a GIP analogue or a pharmaceutically acceptable salt thereof having the general formula (I), wherein Y1 is an amino acid residue of Lys.
[0127] In another embodiment, the above polypeptide compound of the present invention and its pharmaceutically acceptable salt.
[0128] The polypeptide dual agonist compounds and their derivatives provided by the present invention are amphoteric compounds. Those skilled in the art can use acidic or basic compounds to react with them to form salts through known techniques. The acids commonly used to form acid addition salts are: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid; salts include sulfates, pyrosulfates, trifluoroacetates, sulfites, bisulfites, phosphates, hydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, hydrochlorides, bromides, iodides, acetates, propionates, Caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, γ-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, etc., preferably trifluoroacetate. Alkaline substances can also form salts with GLP-1 analogs, and these alkaline substances include ammonium, alkali metal or alkaline earth metal hydroxides, as well as carbonates and bicarbonates, typically sodium hydroxide, potassium hydroxide, ammonium hydroxide, sodium carbonate, potassium carbonate, etc.
[0129] The pharmaceutical composition containing the polypeptide dual agonist compound according to the present invention can be used to treat patients in need of such treatment by parenteral administration. The parenteral administration route can be selected from subcutaneous injection, intramuscular injection or intravenous injection. The polypeptide dual agonist compound of the present invention can also be administered by transdermal route, such as scalp administration via a patch, and an iontophoresis patch can be selected; or by transmucosal route.
[0130] The polypeptide dual agonist compound and its pharmaceutical composition provided by the present invention can be prepared using conventional techniques of the pharmaceutical industry, which include appropriate dissolution and mixing of the components to obtain the desired final composition. For example, the polypeptide dual agonist compound is dissolved in a certain amount of water, wherein the amount of water is slightly less than the final volume of the prepared composition. Isotonic agents, preservatives, surfactants and buffers are added as needed, and isotonic agents are such as sodium chloride, mannitol, glycerol, propylene glycol, sugar or sugar alcohol. Preservatives are such as phenol, o-cresol, p-cresol, m-cresol, methyl parahydroxybenzoate, benzyl alcohol. Suitable buffers are such as sodium acetate, sodium carbonate, glycine, histidine, lysine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and surfactants are such as poloxamer, poloxamer-188, poloxamer-407, Tween-80, Tween-20. And when necessary, use an acid such as hydrochloric acid or a base such as sodium hydroxide aqueous solution to adjust the pH value of the solution, and finally use water to adjust the solution volume to obtain the desired component concentration. In addition to the above ingredients, the pharmaceutical composition provided by the present invention also includes a sufficient amount of basic amino acids or alkaline agents with the same effect to reduce aggregates formed during storage of the composition, such as lysine, histidine, arginine, and imidazole.
[0131] The polypeptide compound and its derivative provided by the invention adopt a solid phase synthesis method, the synthesis carrier is Rink-amide ChemMatrix (Biotage) resin, the α-amino group of the amino acid derivative used in the synthesis process is protected by an Fmoc group (fluorenylcarbonyl), and the side chains of the amino acids are selected from the following protecting groups according to different functional groups: the cysteine side chain thiol group, the glutamine side chain amino group, and the histidine side chain imidazole group are protected by Trt (trityl), the arginine side chain guanidine group is protected by Pbf (2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl), the tryptophan side chain indole group and the lysine side chain amino group are protected by Boc (tert-butyloxycarbonyl), and the threonine side chain hydroxyl group, the tyrosine side chain phenol group, and the serine side chain hydroxyl group are protected by tBu (tert-butyl). During the synthesis process, the carboxyl group of the amino acid residue at the C-terminal end of the polypeptide is first condensed to the polymer insoluble Rink-amide ChemMatrix resin in the form of an amide bond, and then the Fmoc protecting group on the α-amino group is removed with a nitrogen-dimethylformamide (DMF) solution containing 20% piperidine, and then the solid phase carrier is condensed with the next amino acid derivative in the sequence in excess to form an amide bond to connect the peptide chain. Repeat the condensation → washing → deprotection → washing → next round of amino acid condensation to achieve the desired length of the synthesized peptide chain, and finally use a mixed solution of trifluoroacetic acid: water: triisopropylsilane (90:5:5, v:v:v) to react with the resin to cleave the polypeptide from the solid phase carrier, and then precipitate with frozen isopropyl ether to obtain a solid crude product of the polypeptide and polypeptide derivatives. The solid crude polypeptide is dissolved in a mixed solution of acetonitrile / water containing 0.1% trifluoroacetic acid and then purified and separated by a C-18 reverse phase preparative chromatography column to obtain a pure product of the polypeptide and its derivatives.
[0132] The polypeptides and their derivatives synthesized in this specification are shown in Table 1.
[0133] Table 1:
[0134]
[0135]
[0136] Detailed description of the invention
[0137] Unless stated otherwise, the terms used in the specification and claims have the following meanings.
[0138] The amino acid sequences of the present invention contain the standard single-letter or three-letter codes for the twenty amino acids. Unless otherwise specified, all amino acid residues in the present invention are preferably in the L-form. In addition, Aib is α-aminoisobutyric acid, D-Ala is D-alanine
[0139] The term agonist is defined as a substance that activates the receptor type in question:
[0140] The term GLP-1 / GIP dual agonist used in the context of the present invention refers to a substance or ligand that can activate both the GLP-1 receptor and the GIP receptor. In the present invention, the term treatment includes inhibiting, slowing, stopping or reversing the progression or severity of existing symptoms or illnesses.
[0141] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, and most preferably an alkyl group containing 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. More preferred are lower alkyl groups having 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available attachment point. The substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate groups. Methyl, ethyl, isopropyl, tert-butyl, haloalkyl, deuterated alkyl, alkoxy-substituted alkyl and hydroxy-substituted alkyl are preferred in the present invention.
[0142] Different expressions such as “X is selected from A, B, or C”, “X is selected from A, B and C”, “X is A, B or C”, “X is A, B and C” all express the same meaning, that is, X can be any one or more of A, B, C.
[0143] The hydrogen atoms described in the present invention can be replaced by their isotope deuterium, and any hydrogen atom in the example compounds of the present invention can also be replaced by a deuterium atom.
[0144] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.
[0145] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are replaced independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the skilled person can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (e.g. olefinic) bonds.
[0146] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
[0147] "Pharmaceutically acceptable salts" refer to salts of the compounds of the present invention, which are safe and effective when used in mammals and have the desired biological activity. DETAILED DESCRIPTION
[0148] In order to illustrate the present invention in more detail, this specification provides the following specific implementation schemes, but the solutions of the present invention are not limited thereto.
[0149] 1. Experimental reagents
[0150]
[0151]
[0152] 2. Experimental instruments
[0153] Serial number instrument source 1 H-CLASS analytical ultra-high performance liquid chromatography WATERS 2 Xevo LC / MS WATERS 3 Labconco multifunctional freeze dryer Thermo-Fisher Scientific 4. Prep150 Preparative HPLC WATERS 5. Multi-channel high-speed centrifuge Sigma
[0154] 3. Specific implementation plan
[0155] 3.1 Chemical synthesis of compound No. 1:
[0156] 3.1.1. Coupling of Fmoc-L-Lys(Boc)-OH with Rink-amide ChemMatrix resin:
[0157] Weigh Rink-amide ChemMatrix resin (Biotage, 0.1 mmol) and place it in a disposable polypropylene peptide synthesis solid phase reaction tube, add DMF (10 ml) to swell the resin under nitrogen bubbling for 10 minutes, vacuum remove DMF, add DMF (10 ml) to wash the resin, and repeat the washing twice; weigh Fmoc-L-Lys(Boc)-OH (1 mmol), 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazine-4-one (DEPBT) (1 mmol) and diisopropylethylamine (DIEA, 2 mmol), add DMF (10 ml) to dissolve, then add the above solution to the swollen Rink-amide ChemMatrix resin, shake and react at room temperature for 2 hours, after the reaction is completed, wash the resin twice with DMF and dichloromethane (DCM) alternately, and finally wash it with DMF 3 times.
[0158] 3.1.2. Removal of Fmoc protecting group from Fmoc-L-Lys(Boc)-Rink-amide resin:
[0159] Add piperidine / DMF (20%, 10 ml) to the solid phase reaction tube containing Fmoc-L-Lys(Boc)-Rink amide resin, shake and react at room temperature for 10 minutes, then remove the solution, add piperidine / DMF (20%, 10 ml), shake and react at room temperature for 10 minutes, then remove the solution. After the reaction, wash the resin with DMF (10 ml) 4 times.
[0160] 3.1.3. Coupling of peptide chain sequences:
[0161] According to the peptide sequence of compound No. 1 from the amino terminus to the carboxyl terminus (H-Tyr-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Nle-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-NH 2), the amount of amino acid derivatives and condensation reagents and the condensation method and coupling Fmoc-L-Lys(Boc)-OH to Rink-amide The ChemMatrix resin is the same, and the amino acid residues used in the synthesis process are: Fmoc-L-Tyr(tBu)-OH, Fmoc-L-Ala-OH, Fmoc-L-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-L-Thr(tBu)-OH, Fmoc-L-Phe-OH, Fmoc-L-Ser(tBu)-OH, Fmoc-L-Asp(OtBu)-OH, Fmoc-L-Ile-OH, Fmoc-L-Nle-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-L-His(Boc)-OH, Fmoc-L-Gln(Trt)-OH, Fmoc-L-Val-OH, Fmoc-L-Asn(Trt)-OH, Fmoc-L-Trp(Boc)-OH, and Fmoc-L-Leu-OH. Repeating the condensation of amino acid derivatives and Fmoc deprotection ultimately yields a resin peptide containing the polypeptide sequence of compound No. 1.
[0162] 3.1.4. Cleavage of resin peptide:
[0163] The resin peptide obtained in the previous step was washed with DMF and DCM three times in sequence and then vacuum dried. Then, 10 ml of freshly prepared lysis solution (trifluoroacetic acid: triisopropylsilane: water, 90:5:5, v:v:v) was added and shaken for 2 hours at room temperature. After the reaction was completed, the resin was filtered and washed with trifluoroacetic acid twice. After the filtrate was combined, a large amount of frozen anhydrous isopropyl ether was added to precipitate the solid. After centrifugation, the supernatant was removed to obtain a crude polypeptide with compound number 1.
[0164] 3.1.5. Reverse phase liquid chromatography purification of crude peptide:
[0165] The crude peptide was dissolved in a mixed solvent containing 0.1% trifluoroacetic acid and 20% acetonitrile / water, filtered through a 0.22 μm membrane, and separated using a WATERS Prep-150 LC reverse phase high performance liquid chromatography system, with buffers A (0.1% trifluoroacetic acid, 10% acetonitrile, aqueous solution) and B (0.1% trifluoroacetic acid, 90% acetonitrile, aqueous solution). The chromatographic column was an X-SELECT OBDC-18 reverse phase column, and the chromatograph detection wavelength was set to 220 nm during the purification process, with a flow rate of 20 mL / min. The product-related fractions were collected and lyophilized to obtain a pure polypeptide of compound No. 1, with a yield of 20%. The purity and compound identity of the pure polypeptide were determined by analytical high performance liquid chromatography and liquid chromatography / mass spectrometry, wherein the purity was 96.41%, the calculated molecular weight of the compound was: 3501.8, and the measured molecular weight of the compound was: 3501.6.
[0166] 3.2 Chemical synthesis of compound No. 2-33
[0167] The polypeptide compounds of compound No. 2-33 of the present invention were synthesized using the experimental scheme of compound 1, and the purity and molecular weight of the compounds were determined by analytical ultra-high performance liquid chromatography and liquid chromatography / mass spectrometry, as shown in Table 2 below:
[0168]
[0169]
[0170] 3.3 Chemical synthesis of compound No. 34:
[0171] 3.3.1 Coupling of Fmoc-L-Lys(Mtt)-OH with Rink-amide ChemMatrix resin:
[0172] Weigh Rink-amide ChemMatrix resin (0.1 mmol) and place it in a disposable polypropylene solid phase synthesis reaction tube, add DMF (10 ml) to swell the resin for 5 minutes, remove DMF in vacuo, add DMF (10 ml) to wash the resin, and repeat the washing twice; weigh Fmoc-L-Lys(Mtt)-OH (1 mmol), 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazine-4-one (DEPBT) (1 mmol) and DIEA (2 mmol), add DMF (10 ml) to dissolve, add the above solution to the swollen Rink-amide ChemMatrix resin, shake and react at room temperature for 2 hours, after the reaction is completed, wash the resin twice with DMF and dichloromethane (DCM) alternately, and finally wash the resin with DMF 3 times.
[0173] 3.3.2. Fmoc deprotection and peptide chain extension
[0174] The Fmoc deprotection of Fmoc-L-Lys(Mtt)-Rink amide ChemMatrix resin and the subsequent extension of the peptide chain were carried out using the same synthetic method as in Example 1 to obtain a resin peptide containing compound No. 34, wherein the N-terminal amino acid residue was selected to be Boc-L-Tyr(t-Bu)-OH.
[0175] 3.3.3. Mtt deprotection of resin peptides and modification of lysine side chains
[0176] After the peptide-resin extension was completed, a hexafluoroisopropanol / dichloromethane mixed solution (30%, 10 ml) was added, and the mixture was shaken at room temperature for 45 minutes and then removed. Then, a hexafluoroisopropanol / dichloromethane mixed solution (30%, 10 ml) was added, and the mixture was shaken at room temperature for 45 minutes and then removed. After the reaction, the resin was washed 6 times with DMF. Additional coupling / deprotection cycles involving Fmoc-NH-PEG using the Fmoc / tBu solid phase synthesis strategy to extend the lysine side chain 2 -COOH, Fmoc-L-Glu-OtBu and HOOC-(CH 2 ) 16 In all couplings, the reactions were performed at room temperature using 1 mmol of amino acid building block, 1 mmol of DEPBT and 2 mmol of DIEA in DMF for 4 hours.
[0177] 3.3.4. Cleavage and product purification
[0178] The resin peptide obtained in the previous step was washed twice with DMF and DCM in sequence and then vacuum dried, and then a freshly prepared cleavage solution (trifluoroacetic acid: triisopropylsilane: water = 90:5:5, v:v:v) was added and reacted at room temperature for 2 hours under shaking. After the reaction was completed, the resin was filtered and washed twice with trifluoroacetic acid. After the filtrate was combined, a large amount of frozen anhydrous isopropyl ether was added to precipitate the solid, and the supernatant was removed after centrifugation to obtain a crude polypeptide with compound number 34.
[0179] 3.3.5 Reverse phase liquid chromatography purification of compound 34
[0180] The crude peptide of 34 was dissolved in a mixed solvent containing 0.1% trifluoroacetic acid and 20% acetonitrile / water, filtered through a 0.22um membrane, and separated using a WATERS Prep150 LC reverse phase high performance liquid chromatography system, with buffers A (0.1% trifluoroacetic acid, 10% acetonitrile, aqueous solution) and B (0.1% trifluoroacetic acid, 90% acetonitrile, aqueous solution). The chromatographic column was an X-SELECTOBD C-18 reverse phase chromatographic column, and the chromatograph detection wavelength was set to 220nm and the flow rate was 20mL / min during the purification process. The product-related fractions were collected and lyophilized to obtain a pure polypeptide of compound number 34, with a yield of 18%. The purity of the pure polypeptide was determined by analytical high performance liquid chromatography and liquid chromatography / mass spectrometry, and the purity and compound were 97.23% and the molecular weight of the compound was 5046.6.
[0181] 3.4 Chemical synthesis of compound numbers 35-47
[0182] The polypeptide compounds Nos. 35-47 of the present invention were synthesized using the experimental scheme of compound 34, and the purity and molecular weight of the compounds were determined by analytical HPLC and LC / MS, as shown in Table 3 below.
[0183]
[0184]
[0185] Biological test evaluation
[0186] The present invention is further described and explained below in conjunction with test examples, but these embodiments are not intended to limit the scope of the present invention.
[0187] 1. Experimental reagents
[0188]
[0189] 2. Experimental instruments
[0190]
[0191]
[0192] 3. Test Case
[0193] 3.1. Evaluation of the agonist activity of the test compounds at the glucagon-like peptide-1 receptor (GLP-1R)
[0194] 3.1.1 Experimental Purpose
[0195] The purpose of this test case is to measure the agonist activity of the numbered compounds at the glucagon-like peptide-1 receptor (GLP-1R)
[0196] 3.1.2 Experimental methods:
[0197] The frozen CHO-K1 / GLP-1R / CRE-luc stable cell line was taken out from the liquid nitrogen tank, quickly thawed in a 37°C water bath, resuspended with DMEM / F12 medium (Gibco Cat#11330032), washed once after centrifugation, resuspended with experimental buffer, i.e. DMEM / F12 medium containing 0.1% casein (Sigma Cat#C3400), and the cell density was adjusted with experimental buffer. The cells were plated in a 384-well plate (Sigma Cat#CLS4514) at a density of 2500 cells / 5 μL / well, and then 2.5 μL of IBMX working solution (Sigma Cat#I7018) prepared in buffer was added to each well, with a final concentration of IBMX of 0.5 mM, and 2.5 μL of gradient diluted peptide samples, centrifuged at 1000 rpm for 1 min, shaken for 30 seconds to mix, and incubated at room temperature for 30 minutes. Use CisbiocAMP-Gs Dynamic kit (Cisbio Cat#62AM4PEC) for detection, dilute cAMP-d2 and Anti-cAMP-Eu3+-Cryptate 20 times with cAMP Lysis & Detection Buffer and mix well. Add 5μL of diluted cAMP-d2 solution to each well, then add 5μL of diluted Anti-cAMP-Eu3+-Cryptate solution, shake for 30 seconds to mix well, and incubate at room temperature in the dark for 1 hour.
[0198] 3.1.3 Experimental data processing method:
[0199] The HTRF signal was read using a Biotek Synergy H1 microplate reader with an excitation wavelength of 320 nm and emission wavelengths of 620 nm and 665 nm. The signal ratio (665 nm / 620 nm*10,000) was calculated and the signal ratio was nonlinearly fitted with a four-parameter equation to the sample concentration in GraphPad Prism 6 to obtain the EC 50 For specific data, see Table 4 below.
[0200] 3.2. Evaluation of the agonist activity of the test compounds at the glucose-dependent insulin-releasing peptide receptor (GIPR)
[0201] 3.2.1 Experimental Purpose
[0202] Test number compound agonist activity at glucose-dependent insulin-releasing peptide receptor (GIPR) 3.2.2 Experimental method:
[0203] Wild-type CHO-K1 cells were collected, the cell suspension was adjusted to an appropriate density, and plated in a 6-well plate with 2 mL per well, and placed in a 37°C, 5% CO 2 The cells were attached to the wall in an incubator overnight, and the transfection mixture (hGIPR plasmid, Fugene HD (Promega Cat#E2311), OptiMEM (Gibco Cat#31985070) was mixed and allowed to stand at room temperature for 15 minutes, and then added to the corresponding cell wells in a volume of 100 μL. After transfection for 24 hours, hGIPR was overexpressed on the surface of CHO-K1 cells. After the transient transfection, the cells in the 6-well plate were collected and washed once with the experimental buffer, i.e., DMEM / F12 medium (Gibco Cat#11330032) containing 0.1% casein (Sigma Cat#C3400). The cell density was adjusted with the experimental buffer, and the cells were plated in a 384-well plate (Sigma Cat#CLS4514) at a density of 5000 cells / 5 μL / well, and then 2.5 μL of IBMX working solution (Sigma Cat#CLS4514) prepared with the buffer was added to each well. Cat#I7018), IBMX final concentration of 0.5mM, and 2.5μL gradient diluted peptide samples, centrifuged at 1000rpm for 1min, shaken for 30 seconds to mix, and incubated at room temperature for 30 minutes. Use Cisbio cAMP-Gs Dynamic kit (Cisbio Cat#62AM4PEC) for detection, cAMP-d2 and Anti-cAMP-Eu3+-Cryptate were diluted 20 times with cAMP Lysis & Detection Buffer and mixed. Add 5μL of diluted cAMP-d2 solution to each well, then add 5μL of diluted Anti-cAMP-Eu3+-Cryptate solution, shake for 30 seconds to mix, and incubate at room temperature for 1 hour in the dark.
[0204] 3.2.3 Experimental data processing method:
[0205] The HTRF signal was read using a Biotek Synergy H1 microplate reader with an excitation wavelength of 320 nm and emission wavelengths of 620 nm and 665 nm. The signal ratio (665 nm / 620 nm*10,000) was calculated and the signal ratio was nonlinearly fitted with a four-parameter equation to the sample concentration in GraphPad Prism 6 to obtain the EC 50 The specific values are shown in Table 4 below.
[0206] Table 4: Agonist activity of test compounds at human GLP-1R and human GIPR receptors
[0207]
[0208]
[0209] Experimental conclusion
[0210] Some of the tested compounds showed strong agonist activity at both the human GLP-1 receptor and the human GIP receptor, among which compounds 7, 9, 11, 13, 16, 19 or 23 showed agonist activity equivalent to that of natural polypeptides at both the human GLP-1 receptor and the human GIP receptor. The fatty acid-modified compounds all showed strong activity (<0.05 nM) on the GIP receptor. Compared with many GLP-1 receptor agonist polypeptides in the art, these polypeptides showed strong agonist activity at both the human GLP-1 receptor and the human GIP receptor, especially in terms of GIP receptor activity.
Claims
1. A GIP analog or a pharmaceutically acceptable salt thereof, having the following structure:
2. A pharmaceutical composition comprising the GIP analogue or a pharmaceutically acceptable salt thereof as claimed in claim 1, and a pharmaceutically acceptable carrier thereof.
3. Use of the GIP analogue or a pharmaceutically acceptable salt thereof according to claim 1, or the pharmaceutical composition according to claim 2, in the preparation of a medicament for treating non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus or obesity.
4. The GIP analogue or a pharmaceutically acceptable salt thereof according to claim 1, used in combination with other agents simultaneously, separately or sequentially, wherein the agent is one or more selected from metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase inhibitors and sodium glucose transporters.
